VET-MAGAZIN logo
Wie „Supergene“ bei Fischen helfen, neue Arten zu entwickeln
LIB, Hannes Svardal
Liegespuren mit Hautabdrücken von frühen Säugetierverwandten
Lorenzo Marchetti
Salamander leiden unter steigenden Temperaturen
Daniel Rosengren/Zoologische Gesellschaft Frankfurt
Wo Biber Dämme bauen, steigt die Zahl wasserlebender Tierarten
UDE / Sara Schloemer
Wo Biber Dämme bauen, steigt die…
Waldfledermäuse suchen Zuflucht in Siedlungen
Carolin Scholz/Leibniz-IZW
Neue Einblicke in die antivirale Abwehr bei Fledertieren
Zoharby via Wikimedia Commons
Neue Einblicke in die antivirale Abwehr…
Zauneidechsen fühlen sich an Bahngleisen wohl
Thomas Zimmel/VET-MAGAZIN
Wie Haie das Ende der Dinosaurier überstanden
NHM Wien, Iris Feichtinger
Wie Haie das Ende der Dinosaurier…
Speakers at the Merial Conference. From left, Patrick Devauchelle (Animal Oncology Centre, Maisons-Alfort), Dominique Jas (R&D Merial), Catherine Pépin (Technical manager companion animals, Merial), Pascal Fayard (Marketing manager companion an
Merial
Allgemein

Innovative treatment for Feline Injection Site Sarcoma to be launched this autumn

“On average, European veterinary practitioners see between two and three cases of feline sarcoma each year,” reported Pascal Fayard, European marketing manager, citing a survey held among 500 general practitioners in five countries.

. . .

Speaking at a Merial Conference held in Lisbon on 29 of May, on the eve of the congress of European Society of Veterinary Oncology, he announced the European-wide launch, coming autumn, of a novel immunotherapeutic drug, Oncept IL-2, for the treatment of fibrosarcoma in cats.

Interleukin: stimulating anti-tumour defence

“Interleukin 2 (IL-2) stimulates the growth and activity of T-lymphocytes and natural killer cells, the production of other cytokines like interferon gamma (IFN) and may improve the tumour-specific immune response,” explained Hervé Poulet, Head of bio development Europe and R&D leader at Merial. 

“In humans, high-dose systemic IL-2 has been approved for the treatment of metastatic melanoma and renal cell carcinoma”.

However, large doses of systemic IL-2 are associated with several toxic side effects, including the capillary leak syndrome while its clinical efficacy is hampered by the short half-life of IL-2 (a few days).

To overcome this, several local IL-2-delivery systems have been studied, including free recombinant IL-2, or IL-2 expressed by DNA plasmids or viral vectors, IL-2 secreting cells and antibody-targeted IL-2.

The therapeutic effects of local IL-2 therapy have been demonstrated in several cancers, including equine sarcoids, canine melanoma and non-resectable mast cell tumours.

“For feline fibrosarcoma, we chose a canarypox virus vector (ALVAC®) expressing IL-2: it is very safe as it does not replicate and expresses IL-2 locally. It was found to be an efficacious adjunct treatment to surgery and radiotherapy,” Dr Poulet concluded.

Reducing the risk of relapse by 65%

Results of a monocentric controlled clinical trial were presented by Dominique Jas (Merial R&D) to confirm the efficacy and safety of the product. Seventy-one cats with a first occurrence of feline fibrosarcoma were referred for post-surgical radiotherapy.

They were assigned to three treatment groups: controls (surgery + radiotherapy), low-dose IL-2 treatment (surgery + radiotherapy + IL-2) and high-dose IL-2 treatment (surgery + radiotherapy + IL-2). Cats were enrolled 1 month after surgery, which was not necessarily done in referral practices.

However, the percentage of cats with dirty surgical margins was comparable in all groups. Treatment (D0, D7, D14, D21, D35, D49) was initiated the day before the start of radiotherapy (D1 and D3). Cats were checked every three months and underwent a CT scan at 3, 6, 12 and 24 months.

The high-dose group – to test safety – was monitored for a year, the low-dose group – to test efficacy – for two years.

Local ALVAC IL-2-treated cats showed a significantly longer median time to relapse (>730 days) than in the reference treatment group (287 days). Results also showed a significant reduction of relapse risk compared to the control group after two years (65%). Oncept IL-2 was well tolerated, and the time without relapse was significantly increased with no alteration of quality of life.

“This study showed that the control group, that did not undergo immunotherapy, had poorer results than either treatment group – in spite of the cats receiving a total of thirty injections, Dr Jas confirmed, in answer to the question whether treatment injections were not a risk factors for the development of FISS.

Colleagues from Spain, where there is no radiotherapy available for pets, asked about the possible benefits in cats with surgery alone. “We currently only have a claim for an adjunct therapy to surgery and radiotherapy,” stressed Dr Jas, but she added that this was currently being investigated.

An EU-wide launch this autumn

Oncept IL-2, result of a long-standing collaboration between Merial R&D and leading oncology experts, is the first cancer immunotherapeutic drug approved for veterinary use in Europe.

“We’re very excited and proud to announce the forthcoming launch of a new immunotherapy, a recombinant canarypox virus expressing feline IL-2 at the site of injection, added Catherine Pépin, Merial’s technical manager for companion animals. “The claim is for cats with fibrosarcoma (2-5 cm diameter) without metastasis or lymph node involvement, in order to reduce the risk of relapse and to increase the relapse-free interval.”

“We expect to launch Oncept IL-2 throughout the EU this coming autumn, added Pascal Fayard. He also presented the packaging (“one box contains 6 doses, equal to one course of treatment”) and storage requirements (“in the refrigerator, just like vaccines”). However, the expected retail price was not yet known.

Oncept IL-2: Six sessions, five injections, one treatment

Six sessions with local infiltration (five injections each) in the tumour scar tissue are required. The product’s claim is specific: “reducing the risk of relapse and increasing the time to relapse in cats with fibrosarcoma (2-5 cm diameter) without metastasis or lymph node involvement, in addition to surgery and radiotherapy.”

After reconstitution, five subcutaneous injections (0.2 ml each) are made around the tumour excision site: “one injection at each corner and one injection at the centre of a 5 cm x 5 cm square centered on the middle of the surgical scar.”

A treatment course consists of four sessions at 1-week intervals (day 0, D7, D14, D21) followed by two treatment sessions at 2-week intervals (D35, D49). Treatment is started the day before commencing radiation therapy, preferably within one month after surgical excision.

However, no particular precautions are necessary for administration, as “canarypox recombinants are safe, and feline IL-2 has a very low biological activity”.

FISS - First surgical attempt: main prognostic factor

“An association between injections and the development of feline injection-site sarcomas (FISS) was first observed in the late 1980s”, recalled Ana Lara (Royal Veterinary College, UK). Subsequent studies showed a link with a range of injectable drugs triggering local inflammation followed by an abnormal proliferation of fibroblasts and myofibroblasts.

“These sarcomas were found to be highly locally infiltrative but with a relatively low (0-24%) metastatic rate.”

Although it is a neoplasia that is associated to veterinary practice, there is a potential for prevention and early diagnosis: “we know the risk-population (those receiving injections) and the location (site of injection)”.

For these reasons, a benefit-risk analysis is required prior to vaccination while vaccinate in the distal extremities should be considered to maximise the chance of cure in the advent of FISS.

“If FISS is suspected, never perform excisional biopsy - it has a detrimental impact on prognosis,” warned Dr Lara. “In fact, the number one prognostic factor is the first attempt at surgery - which should be aggressive: margins should be 4-5 cm wide and at least 2 fascial layers deep.”

She also recalled the 3-2-1 rule: “biopsy if the lump persists for more than 3 months, if it is larger than 2 cm or if it has appeared within 1 month of injection.” Adding radiotherapy increases the disease-free interval, but not the cure rate – and is not available in all European countries. Chemotherapy is only of interest in cats with unresectable or metastatic tumours.

. . .

Weitere Meldungen

Neuigkeiten aus der Wissenschaft

Eine Kohlmeise blickt mit ihrem linken Auge zu einem Stimulus
Universität Konstanz, Comparative Cognition and Sociality Lab
Die bei uns heimischen Feuersalamander sind eine der vielen Arten, die auf ausreichend Feuchtigkeit angewiesen sind.
Daniel Rosengren/Zoologische Gesellschaft Frankfurt
Rinderstall
Thomas Zimmel/VET-MAGAZIN

Neue Verordnung zu MKS: Importverbot für tierische Produkte aus Ungarn gezielt angepasst

Importverbot gilt ab 14. April 2025 nur mehr für Regionen mit Schutz- oder Sperrzonen - Maßnahmen zum Schutz der Tiergesundheit bleiben aufrecht

Schloss Jelgava - Lettische Universität für Biowissenschaften und Technologie
Pudelek (Marcin Szala) via Wikimedia Commons

Hardenberg Institute vermittelt Veterinär-Studienplätze

Das Hardenberg Institute vermittelt Studieninteressierte aus Österreich und Deutschland an akkreditierte Veterinär-Fakultäten im EU-Ausland

Neues Artenschutzhaus für geschmuggelte Tiere im Tiergarten Schönbrunn eröffnet
Daniel Zupanc

Neues Artenschutzhaus für geschmuggelte Tiere im Tiergarten Schönbrunn eröffnet

Im Tiergarten Schönbrunn wurde am 11. April 2025 das neue Artenschutzhaus eröffnet

Vetmeduni Vienna
Thomas Zimmel/VET-MAGAZIN

ÖTT-Tagung 2025: 20 Jahre Tierschutzgesetz – wo stehen wir?

Die 15. Tagung der Plattform Österreichische Tierärztinnen und Tierärzte für Tierschutz (ÖTT) findet am 8. Mai 2025 online statt.

Grenzübergang Loipersbach – Ágfalva
Steindy via Wikimedia Commons

Maßnahmen gegen Maul- und Klauenseuche: Grenzübergänge vorübergehend geschlossen

Erhöhte Biosicherheitsmaßnahmen für Betriebe, Importstopp für pflanzliche Futtermittel aus betroffenen Regionen, Abstimmung zwischen Behörden läuft gut

KATZENMEDIZIN #23
just4vets

KATZENMEDIZIN #23

Die aktuelle Ausgabe des Fachmagazins für Tierärzt:innen, KATZENMEDIZIN #23, ist soeben erscheinen

Vetmeduni Vienna
Thomas Zimmel/VET-MAGAZIN

Vetmeduni Vienna verschiebt den Tag der offenen Tür

Als Vorsichtsmaßnahme wegen der in der Slowakei und in Ungarn ausgebrochenen Maul- und Klauenseuche (MKS) wird der Tag der offenen Tür in den September 2025 verschoben

Österreichische Tierärztekammer

Tierärztekammer fordert dringende Maßnahmen zur Bekämpfung der Maul- und Klauenseuche (MKS)

MKS-Ausbrüche in der Slowakei und Ungarn weiterhin nicht unter Kontrolle

Präparat von Melina Haring: Kragenechse (Chlamydosaurus kingii), Präparat/Professional, Gewinn: 2. Rang (rote Schleife)
NHM Wien, Wilhelm Bauer

Fünf Erfolge der Präparator*innen für das NHM Wien

Im Februar 2025 fand zum 14. Mal die "European Taxidermy Championships", die Europameisterschaft der Präparator*innen, in Salzburg statt

Teile diesen Bericht auf:

Werbung via Google
Werbung via Google

Buchtipps Buchtipps Buchtipps

Tierarztpraxis gründen und betreiben
Tierarztpraxis gründen und betreiben
(11. Jun. 2025) Der Leitfaden für die Selbstständigkeit in der Tiermedizin…
Suchterkrankung beim Hund
(3. Jun. 2025) Suchterkrankung beim Hund - gibt es das? Offenbar…
Wildtierfindlinge in der Tierarztpraxis
(27. Mai. 2025) Grundlagen der Wildtierhilfe, praktische Anwendung, tierärztliche Versorgung -…
The Equine Distal Limb
(22. Mai. 2025) An Atlas of Clinical Anatomy and Comparative Imaging-…
Tiergestützte Interventionen in der Psychiatrie
(16. Mai. 2025) Grundlagen, Methoden und Praxis der tiergestützten Interventionen in…
Laser Therapy in Veterinary Medicine: Photobiomodulation
(9. Mai. 2025) A comprehensive, up-to-date reference to the clinical applications…

Internationale Veranstaltungen Int. Veranstaltungen Internationale Veranstaltungen

SIVEMAP 2025
SIVEMAP 2025
(31. Mär. 2025) Die SASAP (Serbian Association of Small Animal Practitioners)…
EVECC-Kongress 2025
(1. Mär. 2025) Der 22. European Veterinary Emergency and Critical Care…
FECAVA EuroCongress 2025 in Antwerpen
(17. Feb. 2025) FECAVA lädt Sie vom 3. bis 6. September…
Yaboumba Weltkongress 2025
(17. Feb. 2025) Der XV. Internationale Kongress für Medizin und Chirurgie…
Webinar zum World Veterinary Dermatology Day…
(13. Jan. 2025) Die World Association for Veterinary Dermatology lädt am…
Hill's Global Symposium 2024
(20. Okt. 2024) Hosted by Hill's Pet Nutrition on Oct. 24-25…

Preise und Stipendien Preise und Stipendien Preise und Stipendien

FECAVA-Laboklin-Reisestipendium 2025
FECAVA-Laboklin-Reisestipendium 2025
(19. Mär. 2025) Die Tiermedizin kennt keine Grenzen und FECAVA und…
Bewerbungsfrist für den IGN-Forschungspreis für artgemäße…
(13. Mär. 2025) Der Forschungspreis der Internationalen Gesellschaft für Nutztierhaltung (IGN)…
Felix Wankel Tierschutz-Forschungspreis geht an Studienteam…
(10. Mär. 2025) Alle zwei Jahre zeichnet die Tierärztliche Fakultät der…
Ausschreibung des Herbert-Stiller-Förderpreis für tierfreie Forschung
(6. Mär. 2025) Ärzte gegen Tierversuche fördert tierversuchsfreie Forschungsvorhaben mit 20.000…
Raubtiere vs. Bauern: Ceva Wildlife Research…
(3. Mär. 2025) Der Ceva Wildlife Research Fund unterstützt ein Projekt…
MSD und die FVE fördern 34…
(7. Feb. 2025) MSD Tiergesundheit und der Europäische Tierärzteverband (FVE) zeichnen…